Literature DB >> 27185937

Pravastatin ameliorates placental vascular defects, fetal growth, and cardiac function in a model of glucocorticoid excess.

Caitlin S Wyrwoll1, June Noble2, Adrian Thomson2, Dijana Tesic3, Mark R Miller2, Eva A Rog-Zielinska2, Carmel M Moran2, Jonathan R Seckl2, Karen E Chapman4, Megan C Holmes2.   

Abstract

Fetoplacental glucocorticoid overexposure is a significant mechanism underlying fetal growth restriction and the programming of adverse health outcomes in the adult. Placental glucocorticoid inactivation by 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2) plays a key role. We previously discovered that Hsd11b2(-/-) mice, lacking 11β-HSD2, show marked underdevelopment of the placental vasculature. We now explore the consequences for fetal cardiovascular development and whether this is reversible. We studied Hsd11b2(+/+), Hsd11b2(+/-), and Hsd11b2(-/-) littermates from heterozygous (Hsd11b(+/-)) matings at embryonic day (E)14.5 and E17.5, where all three genotypes were present to control for maternal effects. Using high-resolution ultrasound, we found that umbilical vein blood velocity in Hsd11b2(-/-) fetuses did not undergo the normal gestational increase seen in Hsd11b2(+/+) littermates. Similarly, the resistance index in the umbilical artery did not show the normal gestational decline. Surprisingly, given that 11β-HSD2 absence is predicted to initiate early maturation, the E/A wave ratio was reduced at E17.5 in Hsd11b2(-/-) fetuses, suggesting impaired cardiac function. Pravastatin administration from E6.5, which increases placental vascular endothelial growth factor A and, thus, vascularization, increased placental fetal capillary volume, ameliorated the aberrant umbilical cord velocity, normalized fetal weight, and improved the cardiac function of Hsd11b2(-/-) fetuses. This improved cardiac function occurred despite persisting indications of increased glucocorticoid exposure in the Hsd11b2(-/-) fetal heart. Thus, the pravastatin-induced enhancement of fetal capillaries within the placenta and the resultant hemodynamic changes correspond with restored fetal cardiac function. Statins may represent a useful therapeutic approach to intrauterine growth retardation due to placental vascular hypofunction.

Entities:  

Keywords:  11β-HSD2; developmental programming; fetal heart; glucocorticoids; placenta

Mesh:

Substances:

Year:  2016        PMID: 27185937      PMCID: PMC4896723          DOI: 10.1073/pnas.1520356113

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  46 in total

1.  PPAR gamma is required for placental, cardiac, and adipose tissue development.

Authors:  Y Barak; M C Nelson; E S Ong; Y Z Jones; P Ruiz-Lozano; K R Chien; A Koder; R M Evans
Journal:  Mol Cell       Date:  1999-10       Impact factor: 17.970

2.  Essential role of p38alpha MAP kinase in placental but not embryonic cardiovascular development.

Authors:  R H Adams; A Porras; G Alonso; M Jones; K Vintersten; S Panelli; A Valladares; L Perez; R Klein; A R Nebreda
Journal:  Mol Cell       Date:  2000-07       Impact factor: 17.970

3.  Pravastatin induces placental growth factor (PGF) and ameliorates preeclampsia in a mouse model.

Authors:  Keiichi Kumasawa; Masahito Ikawa; Hiroyasu Kidoya; Hidetoshi Hasuwa; Tomoko Saito-Fujita; Yuka Morioka; Nobuyuki Takakura; Tadashi Kimura; Masaru Okabe
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-27       Impact factor: 11.205

4.  The transfer of pravastatin in the dually perfused human placenta.

Authors:  J Zarek; M K DeGorter; A Lubetsky; R B Kim; C A Laskin; H Berger; G Koren
Journal:  Placenta       Date:  2013-06-05       Impact factor: 3.481

5.  Effects of pravastatin on angiogenic and placental hypoxic imbalance in a mouse model of preeclampsia.

Authors:  Antonio F Saad; Talar Kechichian; Huaizhi Yin; Elena Sbrana; Monica Longo; Michael Wen; Esther Tamayo; Gary D V Hankins; George R Saade; Maged M Costantine
Journal:  Reprod Sci       Date:  2013-06-07       Impact factor: 3.060

6.  Maternal stress alters endocrine function of the feto-placental unit in rats.

Authors:  Jérôme Mairesse; Jean Lesage; Christophe Breton; Bernadette Bréant; Tom Hahn; Muriel Darnaudéry; Suzanne L Dickson; Jonathan Seckl; Bertrand Blondeau; Didier Vieau; Stefania Maccari; Odile Viltart
Journal:  Am J Physiol Endocrinol Metab       Date:  2007-01-30       Impact factor: 4.310

7.  Identification of hypertrophy- and heart failure-associated genes by combining in vitro and in vivo models.

Authors:  Bo Lu; Hongjuan Yu; Maarten Zwartbol; Willem P Ruifrok; Wiek H van Gilst; Rudolf A de Boer; Herman H W Silljé
Journal:  Physiol Genomics       Date:  2012-02-21       Impact factor: 3.107

8.  Developmental programming of adult hyperinsulinemia, increased proinflammatory cytokine production, and altered skeletal muscle expression of SLC2A4 (GLUT4) and uncoupling protein 3.

Authors:  Caitlin S Wyrwoll; Peter J Mark; Trevor A Mori; Brendan J Waddell
Journal:  J Endocrinol       Date:  2008-06-30       Impact factor: 4.286

Review 9.  The atrial natriuretic peptide: a changing view.

Authors:  S Rubattu; M Volpe
Journal:  J Hypertens       Date:  2001-11       Impact factor: 4.844

10.  Glucocorticoid receptor is required for foetal heart maturation.

Authors:  Eva A Rog-Zielinska; Adrian Thomson; Christopher J Kenyon; David G Brownstein; Carmel M Moran; Dorota Szumska; Zoi Michailidou; Jennifer Richardson; Elizabeth Owen; Alistair Watt; Harris Morrison; Lesley M Forrester; Shoumo Bhattacharya; Megan C Holmes; Karen E Chapman
Journal:  Hum Mol Genet       Date:  2013-04-16       Impact factor: 6.150

View more
  7 in total

Review 1.  Antenatal endogenous and exogenous glucocorticoids and their impact on immune ontogeny and long-term immunity.

Authors:  María Emilia Solano; Megan C Holmes; Paul R Mittelstadt; Karen E Chapman; Eva Tolosa
Journal:  Semin Immunopathol       Date:  2016-07-28       Impact factor: 9.623

Review 2.  Treating the dysfunctional placenta.

Authors:  Colin P Sibley
Journal:  J Endocrinol       Date:  2017-05-08       Impact factor: 4.286

3.  Antenatal dexamethasone treatment transiently alters diastolic function in the mouse fetal heart.

Authors:  E J Agnew; A Garcia-Burgos; R V Richardson; H Manos; A J W Thomson; K Sooy; G Just; N Z M Homer; C M Moran; P J Brunton; G A Gray; K E Chapman
Journal:  J Endocrinol       Date:  2019-06-01       Impact factor: 4.286

4.  The Placental Transcriptome in Late Gestational Hypoxia Resulting in Murine Intrauterine Growth Restriction Parallels Increased Risk of Adult Cardiometabolic Disease.

Authors:  Alison Chu; David Casero; Shanthie Thamotharan; Madhuri Wadehra; Amy Cosi; Sherin U Devaskar
Journal:  Sci Rep       Date:  2019-02-04       Impact factor: 4.379

5.  Analysis of Placental Arteriovenous Formation Reveals New Insights Into Embryos With Congenital Heart Defects.

Authors:  Jacinta I Kalisch-Smith; Emily C Morris; Mary A A Strevens; Andia N Redpath; Kostantinos Klaourakis; Dorota Szumska; Jennifer E Outhwaite; Xin Sun; Joaquim Miguel Vieira; Nicola Smart; Sarah De Val; Paul R Riley; Duncan B Sparrow
Journal:  Front Genet       Date:  2022-01-19       Impact factor: 4.599

Review 6.  Glucocorticoids, antenatal corticosteroid therapy and fetal heart maturation.

Authors:  Emma J Agnew; Jessica R Ivy; Sarah J Stock; Karen E Chapman
Journal:  J Mol Endocrinol       Date:  2018-05-02       Impact factor: 5.098

Review 7.  Recent Advances in Placenta-Heart Interactions.

Authors:  Cheryl L Maslen
Journal:  Front Physiol       Date:  2018-06-14       Impact factor: 4.566

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.